Clinical trial · Interventional
Comparing Palliative Radiotherapy With or Without Carboplatin
Phase-3 Study, Randomized, Controlled, Multi-center, Double Blind, Comparing Palliative Radiotherapy With or Without Carboplatin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was stopped due to insufficient recruitment.
Summary
Brief summary (as posted)
The study population has locally advanced or metastatic bronchial or head and neck cancer. This study assesses the value of concomitant chemo/radiotherapy with carboplatin daily during metastatic radiotherapy versus radiotherapy alone. The realization of a systemic treatment during the radiotherapy could make it possible to obtain a benefit on the control of the evolution of the metastases and thus of the pains generated, as well as on the quality of life of the patients. In addition, a benefit in overall survival is possible.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| irradiation + carboplatin | Combination Product | — | UNRESOLVED |
| irradiation + placebo | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- irradiation + carboplatin
- description
- Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
- interventionNames
- Combination Product: irradiation + carboplatin
- type
- PLACEBO_COMPARATOR
- label
- irradiation + placebo
- description
- Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
- interventionNames
- Combination Product: irradiation + placebo
Primary outcomes (1)
- measure
- Local progression-free survival of chemo radiotherapy compared with placebo-associated radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with locally advanced or metastatic bronchial or head and neck cancer * Patient require palliative radiotherapy * Age ≥ 18 years * PS ≤ 2 * Obtaining the signed written consent of the patient * Patient affiliated to a social security scheme Exclusion Criteria: * Other chemotherapy or targeted therapy * Prior radiation * Patients with thrombopenia \< 100 000 * Patients with neutropenia \< 2000 * Patients with renal clearance \< 20 mL/min * Known hypersensitivity to platinum salt * Treatment with phenytoin or fosphenytoin * In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine * Unchecked diabetes * hemorrhagic tumor * Refusal of participation or inability to issue informed consent * Person deprived of liberty or adult under guardianship * Minor patients, pregnant or lactating women * Participation in other interventional study
References
Publications (0)
Data not yet available